Depression-like changes of the sleep-EEG during high dose corticosteroid treatment in patients with multiple sclerosis

Psychoneuroendocrinology

Volumn 28, Issue 6, 2003, Pages 780-795

  Antonijevic, Irina A ^a,b   Steiger, Axel ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Res Labs of Sehering AG Berlin   (Germany)

Author keywords

Corticosteroid; EEG; HPA; Major depression; Multiple sclerosis; Sleep

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MOOD; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REM SLEEP; SLEEP; SLEEP STAGE; SLOW WAVE SLEEP;

EID: 0037840278     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4530(02)00085-9     Document Type: Article

References (46)

1. Antoni F.A. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front. Neuroendocrinol. 14:1993;76-122.
2. Antonijevic I.A., Murck H., Frieboes R.M., Steiger A. Sexually dimorphic effects of GHRH on sleep-endocrine activity in patients with depression and normal controls - part I: the sleep EEG. Sleep Res. Online. 3:2000;5-13.
3. Armitage R., Emslie G.J., Hoffmann R.F., Rintelmann J., Rush A.J. Delta sleep EEG in depressed adolescent females and healthy controls. J. Affect. Disord. 63:2001;139-148.
4. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry. 4:1961;561-567.
5. Benca R.M., Obermeyer W.H., Thisted R.A., Gillin J.C. Sleep and psychiatric disorders. A meta-analysis. Arch. Gen. Psychiatry. 49:1992;651-668.
6. Bohlhalter S., Murck H., Holsboer F., Steiger A. Cortisol enhances non-REM sleep and growth hormone secretion in elderly subjects. Neurobiol. Aging. 18:1997;423-429.
7. Born J., De Kloet E.R., Wenz H., Kern W., Fehm H.L. Gluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors. Am. J. Physiol. 260:1991;E183-E188.
8. Buysse D.J., Frank E., Lowe K.K., Cherry C.R., Kupfer D.J. Electroencephalographic sleep correlates of episode and vulnerability to recurrence in depression. Biol. Psychiatry. 41:1997;406-418.
9. Chofflon M., Juillard C., Juillard P., Gauthier G., Grau G.E. Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis. Eur. Cytokine Netw. 3:1992;523-531.
10. De Maertelaer V., Hoffman G., Lemaire M., Mendlewicz J. Sleep spindle activity changes in patients with affective disorders. Sleep. 10:1987;443-451.
11. Driver H.S., Dijk D.J., Werth E., Biedermann K., Borbély A.A. Sleep and the sleep electroencephalogram across the menstrual cycle in young healthy women. J. Clin. Endocrinol. Metab. 81:1996;728-735.
12. Fassbender K., Schmidt R., Mossner R., Kischka U., Kuhnen J., Schwartz A., et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch. Neurol. 55:1998;66-72.
13. Friess E., von Bardeleben U., Wiedemann K., Lauer C., Holsboer F. Effects of pulsatile cortisol infusion on sleep-EEG and nocturnal growth hormone release in healthy men. J. Sleep Res. 3:1994;73-79.
14. Friess E., Trachsel L., Guldner J., Schier T., Steiger A., Holsboer F. DHEA administration increases rapid eye movement sleep and EEG power in the sigma frequency range. Am. J. Physiol. 268:1995;E107-E113.
15. Garland E.J., Zis A.P. Multiple sclerosis and affective disorders. Can. J. Psychiatry. 36:1991;112-117.
16. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
17. Hauser S.L., Doolittle T.H., Lincoln R., Brown R.H., Dinarello C.A. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 40:1990;1735-1739.
18. Heck S., Bender K., Kullmann M., Gottlicher M., Herrlich P., Cato A.C. I kappaB alpha-independent downregulation of NF-kappaB activity by glucocorticoid receptor. EMBO J. 16:1997;4698-4707.
19. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501.
20. Holsboer F., Grasser A., Friess E., Wiedemann K. Steroid effects on central neurons and implications for psychiatric and neurological disorders. Ann. N.Y. Acad. Sci. 746:1994;345-359.
21. Kupfer D.J., Grochocinski V.J., McEachran A.B. Relationship of awakening and delta sleep in depression. Psychiatry Res. 19:1986;297-304.
22. Kupfer D.J., Frank E., McEachran A.B., Grochocinski V.J. Delta sleep ratio. A biological correlate of early recurrence in unipolar affective disorder. Arch. Gen. Psychiatry. 47:1990;1100-1105.
23. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
24. Lancel M., Crönlein T.A., Faulhaber J. Role of GABAA receptors in sleep regulation. Differential effects of muscimol and midazolam on sleep in rats. Neuropsychopharmacology. 15:1996;63-74.
25. Lancel M., Mathias S., Faulhaber J., Schiffelholz T. Effect of interleukin-1 beta on EEG power density during sleep depends on circadian phase. Am. J. Physiol. 270:1996;R830-R837.
26. Levic Z., Micic D., Nikolic J., Stojisavljevic N., Sokic D., Jankovic S., Kendereski A., Mavra M. Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test. J. Endocrinol. Invest. 19:1996;30-34.
27. Liberzon I., Lopez J.F., Flagel S.B., Vazquez D.M., Young E.A. Differential regulation of hippocampal glucocorticoid receptors mRNA and fast feedback: relevance to post-traumatic stress disorder. J. Neuroendocrinol. 11:1999;11-17.
28. Michelson D., Stone L., Galliven E., Magiakou M.A., Chrousos G.P., Sternberg E.M., Gold P.W. Multiple sclerosis is associated with alterations in hypothalamic-pituitary-adrenal axis function. J. Clin. Endocrinol. Metab. 79:1994;848-853.
29. Mikova O., Yakimova R., Bosmans E., Kenis G., Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol. 11:2001;203-208.
30. Miller L.G., Galpern W.R., Dunlap K., Dinarello C.A., Turner T.J. Interleukin-1 augments gamma-aminobutyric acidA receptor function in brain. Mol. Pharmacol. 39:1991;105-108.
31. Mohr D.C., Goodkin D.E., Islar J., Hauser S.L., Genain C.P. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch. Neurol. 58:2001;1081-1086.
32. Mullington J., Korth C., Hermann D.M., Orth A., Galanos C., Holsboer F., Pollmacher T. Dose-dependent effects of endotoxin on human sleep. Am. J. Physiol. 278:2000;R947-R955.
33. Opp M., Obál F. Jr., Krueger J.M. Corticotropin-releasing factor attenuates interleukin 1-induced sleep and fever in rabbits. Am. J. Physiol. 257:1989;R528-R535.
34. Payne L.C., Obal F.J., Krueger J.M. Hypothalamic releasing hormones mediating the effects of interleukin-1 on sleep. J. Cell. Biochem. 53:1993;309-313.
35. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
36. Prickett T.C.R., Inder W.J., Evans M.J., Donald R.A. Interleukin-1 potentiates basal and AVP-stimulated ACTH secretion in vitro - The role of CRH pre-incubation. Horm. Metab. Res. 32:2000;350-354.
37. Rechtschaffen, A., Kales, A., 1968. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Bethesda, MD, US Department of Health, Education & Welfare, Neurological Information Network.
38. Riemann D., Berger M., Voderholzer U. Sleep and depression - results from psychobiological studies: an overview. Biol. Psychol. 57:2001;67-103.
39. Schöbitz B., Reul J.M., Holsboer F. The role of the hypothalamic-pituitary-adrenocortical system during inflammatory conditions. Crit. Rev. Neurobiol. 8:1994;263-291.
40. Schöbitz B., Sutanto W., Carey M.P., Holsboer F., de Kloet E.R. Endotoxin and interleukin 1 decrease the affinity of hippocampal mineralocorticoid (type I) receptor in parallel to activation of the hypothalamic-pituitary-adrenal axis. Neuroendocrinology. 60:1994;124-133.
41. Steiger A., Holsboer F. Neuropeptides and human sleep. Sleep. 20:1997;1038-1052.
42. Steiger A., von Bardeleben U., Herth T., Holsboer F. Sleep EEG and nocturnal secretion of cortisol and growth hormone in male patients with endogenous depression before treatment and after recovery. J. Affect. Disord. 16:1989;189-195.
43. Takahashi S., Tooley D.D., Kapas L., Fang J., Seyer J.M., Krueger J.M. Inhibition of tumor necrosis factor in the brain suppresses rabbit sleep. Pflugers Archiv - Eur. J. Physiol. 431:1995;155-160.
44. Wandinger K.P., Wessel K., Trillenberg P., Heindl N., Kirchner H. Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients. Acta Neurol. Scand. 97:1998;359-365.
45. Webster J.C., Jewell C.M., Bodwell J.E., Munck A., Sar M., Cidlowski J.A. Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J. Biol. Chem. 272:1997;9287-9293.
46. Zorzon M., de Masi R., Nasuelli D., Ukmar M., Mucelli R.P., Cazzato G. Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J. Neurol. 248:2001;416-421.